PDCD1 and ovarian carcinoma: ,174 Pembrolizumab, an antibody specific for PD-1, prevents PD-1 ligation by both PD-L1 and PD-L2.175, 176, 177 Pembrolizumab combined with niraparib appeared to be well tolerated in platinum-sensitive ovarian cancer, providing new treatment options for patients.177